Genmab A/S (NASDAQ:GMAB) Rating Increased to Outperform at Leerink Partners

Leerink Partners upgraded shares of Genmab A/S (NASDAQ:GMAB) from a market perform rating to an outperform rating in a report issued on Thursday, Marketbeat reports. The firm currently has $27.00 price target on the stock.

Several other equities analysts also recently weighed in on the company. Sanford C. Bernstein upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, December 20th. HC Wainwright restated a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a research report on Thursday, January 23rd. Finally, BMO Capital Markets restated an “outperform” rating and issued a $48.00 target price (up previously from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $42.17.

Genmab A/S Trading Up 6.2 %

Shares of GMAB stock opened at $20.92 on Thursday. The company has a market capitalization of $13.84 billion, a P/E ratio of 20.31, a P/E/G ratio of 0.54 and a beta of 0.96. The business’s 50 day moving average is $20.68 and its two-hundred day moving average is $23.21. Genmab A/S has a 12-month low of $18.64 and a 12-month high of $31.88.

Genmab A/S (NASDAQ:GMAB) last released its earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, beating the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. On average, research analysts predict that Genmab A/S will post 1.25 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Genmab A/S

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Marshall Wace LLP increased its stake in Genmab A/S by 162.2% during the fourth quarter. Marshall Wace LLP now owns 1,122,296 shares of the company’s stock worth $23,422,000 after acquiring an additional 694,243 shares during the last quarter. NewEdge Advisors LLC increased its stake in Genmab A/S by 12.7% during the fourth quarter. NewEdge Advisors LLC now owns 19,304 shares of the company’s stock worth $403,000 after acquiring an additional 2,171 shares during the last quarter. Barclays PLC increased its stake in Genmab A/S by 1,072.8% during the fourth quarter. Barclays PLC now owns 2,498 shares of the company’s stock worth $52,000 after acquiring an additional 2,285 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in Genmab A/S during the fourth quarter worth $2,463,000. Finally, Renaissance Technologies LLC increased its stake in Genmab A/S by 7.8% during the fourth quarter. Renaissance Technologies LLC now owns 1,926,150 shares of the company’s stock worth $40,199,000 after acquiring an additional 139,722 shares during the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.